▲ bullish
Impact
PhaseApproved (commercial stage)
Time to marketAlready approved and commercialized. The next label expansion (infant atopic dermatitis) has a PDUFA decision date of February 23, 2027.
ZORYVE roflumilast Updated Nov 13
99days
Next catalyst
PDUFA date · Feb 23, 2027 · mild to moderate atopic dermatitis in infants aged 3 to 24 months
What to watch
The next hard catalyst is the FDA PDUFA decision on February 23, 2027 for ZORYVE cream 0.05% in infants aged 3-24 months with atopic dermatitis. Approval would expand the addressable patient population and support the company's 2027 revenue inflection narrative; a CRL would remove that near-term growth driver but not threaten the core commercial business, which is already generating over $500M in annual revenue.
Bull case
- Strong commercial momentum: ZORYVE net product revenue reached $143.9M in Q3 2026, up 45% year-over-year and 11% sequentially, with full-year 2026 guidance raised to $535-545 million.
- Expanding label: ZORYVE is now approved across three major inflammatory skin conditions (plaque psoriasis, atopic dermatitis, seborrheic dermatitis) with multiple formulations (cream 0.3%, 0.15%, 0.05% and foam 0.3%), making it the #1 prescribed branded topical therapy across these indications.
- Upcoming PDUFA catalyst: The FDA accepted the sNDA for ZORYVE cream 0.05% in infants aged 3-24 months with atopic dermatitis, with a PDUFA date of February 23, 2027, which could open a new patient population.
Bear case
- Insider selling: Multiple executives (CEO Todd Watanabe, CMO Patrick Burnett, CLO Masaru Matsuda) sold shares in early November 2026 near $31-34, near the top of the 52-week range, per SEC Form 4 filings.
- EPS miss: Arcutis missed Q3 2026 earnings expectations as SG&A spending jumped to $99.6M (from $62.4M a year ago) to fund sales force expansion, pressuring near-term profitability.
- Competitive pressure: ZORYVE faces competition from topical steroids, other PDE4 inhibitors, and JAK inhibitors in dermatology; a Seeking Alpha analyst downgraded the stock to Hold citing intense competition and slow growth.